SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
NCT04764214
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
61
Enrollment
OTHER
Sponsor class
Conditions
NSCLC Stage IV
EGFR Activating Mutation
Interventions
DRUG:
3rd generation EGFR-TKI
RADIATION:
Consolidative SRT
Sponsor
Fudan University